SWTX - ערך חשבונאי למניה SpringWorks Therapeutics Inc.
SpringWorks Therapeutics (SWTX) is scaling sales of its first targeted drug and expanding its pipeline. This GURU.Markets book value per share chart visualizes this process, where the 5.52 mark indicates the net asset level. FDA patents ensure a monopoly position, although financial stability depends on clinical trial outcomes and the actual size of the addressable market.
%20%D7%94%D7%95%D7%9F%20%D7%A2%D7%A6%D7%9E%D7%99%20%D7%9C%D7%9E%D7%A0%D7%99%D7%94&width=1200&height=400&colorIndex=0&v=mvouo2ve.rkk-7albim8&start=20220704&end=20261026&filename=GURU_Markets_-_SWTX_-_SpringWorks-Therapeutics_-_Equity-per-Share "SpringWorks Therapeutics (SWTX) - נכסים נקיים למניה בודדת מ-04.07.2022 עד 12.07.2025 | 👁️GURU.Markets👁️")
SWTX (springworkstx.com): פילוחים אנליטיים ודוחות לפי אינדיקטורים
To minimize investment risks, it is necessary to separate market noise from the actual value of the issuer's assets. Book value per share data, reflecting the ratio of equity minus intangible assets to the number of shares, confirm the financial stability of SpringWorks Therapeutics (SWTX), which is bolstered by exclusive patents for the drug Ogsiveo and the ability to exercise pricing power within the orphan oncology segment.